Your browser doesn't support javascript.
loading
Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation.
Chukwu, Chukwuma A; Wu, Henry H L; Pullerits, Kairi; Garland, Shona; Middleton, Rachel; Chinnadurai, Rajkumar; Kalra, Philip A.
Afiliación
  • Chukwu CA; Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Salford M6 8HD, UK.
  • Wu HHL; Renal Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, The University of Sydney, Sydney, NSW 2065, Australia.
  • Pullerits K; Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M1 7HR, UK.
  • Garland S; Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M1 7HR, UK.
  • Middleton R; Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Salford M6 8HD, UK.
  • Chinnadurai R; Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Salford M6 8HD, UK.
  • Kalra PA; Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M1 7HR, UK.
J Clin Med ; 13(7)2024 Mar 24.
Article en En | MEDLINE | ID: mdl-38610636
ABSTRACT

Introduction:

Post-transplant malignancy is a significant cause of morbidity and mortality following kidney transplantation often emerging after medium- to long-term follow-up. To understand the risk factors for the development of de novo post-transplant malignancy (DPTM), this study aimed to assess the incidence, risk factors, and outcomes of DPTM at a single nephrology centre over two decades.

Methods:

This retrospective cohort study included 963 kidney transplant recipients who underwent kidney transplantation between January 2000 and December 2020 and followed up over a median follow-up of 7.1 years (IQR 3.9-11.4). Cox regression models were used to identify the significant risk factors of DPTM development, the association of DPTM with graft survival, and mortality with a functioning graft.

Results:

In total, 8.1% of transplant recipients developed DPTM, and the DPTM incidence rate was 14.7 per 100 patient-years. There was a higher mean age observed in the DPTM group (53 vs. 47 years, p < 0.001). The most affected organ systems were genitourinary (32.1%), gastrointestinal (24.4%), and lymphoproliferative (20.5%). Multivariate Cox analysis identified older age at transplant (aHR 9.51, 95%CI 2.60-34.87, p < 0.001) and pre-existing glomerulonephritis (aHR 3.27, 95%CI 1.10-9.77, p = 0.03) as significant risk factors for DPTM. Older age was significantly associated with poorer graft survival (aHR 8.71, 95%CI 3.77-20.20, p < 0.001). When age was excluded from the multivariate Cox model, DPTM emerged as a significant risk factor for poor survival (aHR 1.76, 95%CI 1.17-2.63, p = 0.006).

Conclusion:

These findings underscore the need for tailored screening, prevention, and management strategies to address DPTM in an aging and immunosuppressed kidney transplant population.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article